SyneuRx International (Taiwan) Corp. – Trademark Portfolio

Entity Type: 03

SyneuRx International (Taiwan) Corp. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 10 filings in this category. Currently, 9 trademarks are registered. Notable registered marks include NABEN, CLOZABEN, SYNSERIN, SYNXYRIN, and NEUSERINE. The owner is based in New Taipei City.

20F.-10, No.99, Sec. 1

Xintai 5th Rd., Xizhi Dist

New Taipei City 221 , TW

10 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

SyneuRx International (Taiwan) Corp.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (10 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does SyneuRx International (Taiwan) Corp. have?

SyneuRx International (Taiwan) Corp. has 10 U.S. trademarks filed with the USPTO. Of these, 9 registered, 1 abandoned.

What trademark classes does SyneuRx International (Taiwan) Corp. file in?

SyneuRx International (Taiwan) Corp. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are SyneuRx International (Taiwan) Corp.'s most well-known trademarks?

SyneuRx International (Taiwan) Corp.'s registered trademark portfolio includes well-known marks such as NABEN, CLOZABEN, SYNSERIN, SYNXYRIN, and NEUSERINE. These are among 9 currently registered trademarks in the portfolio.

What is SyneuRx International (Taiwan) Corp.'s trademark registration success rate?

SyneuRx International (Taiwan) Corp. has a 90% trademark registration rate, with 9 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.